Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer
João Lobo(Universidade do Porto), Robert J. Hamilton(Engineers Without Borders Canada), Michael A.S. Jewett(Princess Margaret Cancer Centre), Leendert H. J. Looijenga(University Medical Center Utrecht), Aaron R. Hansen(Princess Margaret Cancer Centre), Kopika Kuhathaas(University Health Network), Philippe L. Bédard(Princess Margaret Cancer Centre), Eshetu G. Atenafu(Princess Margaret Cancer Centre), Lynn Anson‐Cartwright(University Health Network), Ricardo Leão(Hospital Braga), Peter Chung(Princess Margaret Cancer Centre), Annette van den Berg(Princess Máxima Center), Martin O’Malley(Princess Margaret Cancer Centre), Padraig Warde(University Health Network), Ad Gillis(Princess Máxima Center), Joan Sweet(University Health Network)
Cited by 69
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
|New England Journal of Medicine|1997|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k